During the corresponding time, Centogene N V recorded a revenue increase by 2.16 % year on year, While revenue at the Centogene N V 's corporate clients
Centogene N V's Comment on Sales, Marketing and Customers
The company operates through two primary business segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment offers products and services to pharmaceutical partners, including target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank Licenses and Insight Reports. Revenue in this segment is mainly derived from collaboration agreements with pharmaceutical partners. The Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through distribution partners and clients such as physicians, laboratories, and hospitals. It offers a diagnostic testing portfolio for rare diseases that includes over 19,000 genes and approximately 5,000 different tests. The company introduced the CENTOGENE MOx multiomic testing portfolio and its expanded MOx 2.0 solution, which integrates DNA sequencing, biochemical testing, and RNA sequencing for comprehensive analysis. Additionally, CentoCloud, a cloud-based software-as-a-service platform, was launched to assist laboratories in analyzing, interpreting, and reporting genomic variants for rare disease diagnostics, addressing the need for local genetic sequencing and bioinformatic expertise.
Critical Path Institute (C-Path) and Centogene N.V. (CNTG) have recently signed a Memorandum of Understanding (MOU) to enhance collaboration in the field of lysosomal diseases (LDs). The partnership aims to accelerate drug development for LDs, a group of rare and neurodegenerative conditions, ultimately improving the quality of life for those affected.Details of the Collaboration:C-Path, known for its expertise in forming collaborations that expedite drug development, and Centogene, a leading life science partner specializing in data-driven solutions for rare and neurodegenerative diseases, have joined forces to tackle LDs. LDs are a group of disorders caused by a malfunction in the lysosomal function, leadi...
Centogene, a global leader in genetic diagnostics, has made groundbreaking strides in revolutionizing the diagnosis and understanding of rare and neurodegenerative diseases. With their biodatabank incorporating disease insights from over 850,000 diverse patients, Centogene has fueled the diagnosis of more than 2,500 rare and neurodegenerative diseases, published over 300 peer-reviewed articles, and collaborated with 48 pharmaceutical companies. This article will outline the facts and assess the significant impact of these achievements on Centogene.Understanding the Biodatabank:Centogene s biodatabank forms the foundation of their genetic diagnostics capabilities. Through the collection and analysis of releva...
In a groundbreaking collaboration, Centogene N.V. and Takeda have pledged to enhance their strategic partnership to provide crucial genetic testing for patients battling Lysosomal Storage Disorders (LSDs). This partnership expansion is a significant milestone for both companies and has far-reaching implications for the diagnosis and treatment of rare and neurodegenerative diseases.Global biotechnology leader, Centogene N.V., renowned for being the frontrunner in data-driven solutions for rare and neurodegenerative diseases, announced the extension of its ongoing partnership with Takeda, a global pharmaceutical company. The primary focus of their collaboration is to deliver accurate and efficient diagnoses fo...
Centogene N V’s Comment on Sales, Marketing and Customers
The company operates through two primary business segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment offers products and services to pharmaceutical partners, including target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank Licenses and Insight Reports. Revenue in this segment is mainly derived from collaboration agreements with pharmaceutical partners. The Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through distribution partners and clients such as physicians, laboratories, and hospitals. It offers a diagnostic testing portfolio for rare diseases that includes over 19,000 genes and approximately 5,000 different tests. The company introduced the CENTOGENE MOx multiomic testing portfolio and its expanded MOx 2.0 solution, which integrates DNA sequencing, biochemical testing, and RNA sequencing for comprehensive analysis. Additionally, CentoCloud, a cloud-based software-as-a-service platform, was launched to assist laboratories in analyzing, interpreting, and reporting genomic variants for rare disease diagnostics, addressing the need for local genetic sequencing and bioinformatic expertise.
Sources:
Centogene N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Centogene N v’s corporate clients.
For your research, we’ve provided 9 tables on Centogene N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
